TrialRP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Trial details
- Registry ID
- NCT01490086
- Phase
- Phase 2
Drug research
aripiprazole
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Abilify
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RP5063 in Subjects With Schizophrenia or Schizoaffective DisorderNCT01490086 | Reviva Pharmaceuticals | Phase 2 | Completed | 2013-03Actual |
| Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 | Minerva Neurosciences | Phase 3 | Recruiting | 2027-12Estimated |
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Trial details
- Registry ID
- NCT07565428
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |